Diabetes Care, Vol 17, Issue 8 818-823, Copyright © 1994 by American Diabetes Association

ARTICLES

Platelet plasminogen activator inhibitor 1 in patients with type II diabetes

R Jokl, M Laimins, RL Klein, TJ Lyons, MF Lopes-Virella and JA Colwell
Ralph H. Johnson Department of Veterans Affairs Medical Center, Charleston, South Carolina 29401.

OBJECTIVE--To compare platelet plasminogen activator inhibitor 1 (PAI-1) concentration in type II diabetic patients and healthy control subjects. RESEARCH DESIGN AND METHODS--We studied a group of 12 diabetic patients whose disease was controlled by diet or sulfonylurea therapy and a group of 17 nondiabetic control subjects. All subjects were free of clinically advanced vascular disease. PAI-1 antigen concentrations were measured in 5 x 10(8) isolated platelets, which were lysed by 1% Triton X-100. RESULTS--Mean platelet PAI-1 was significantly higher in diabetic patients (264 +/- 83 ng/5 x 10(8) platelets) compared with control subjects (202 +/- 71 ng/5 x 10(8) platelets) (P < 0.05). A significant independent positive correlation was found between platelet PAI-1 concentrations and fasting plasma specific insulin levels in the diabetic patients (r = 0.63, P = 0.03). CONCLUSIONS--These findings suggest that 1) a higher platelet PAI-1 concentration may contribute to enhanced thrombosis in type II diabetes and 2) megakaryocyte PAI-1 synthesis may be under the control of insulin.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				I. W Campbell Pioglitazone -- an oral antidiabetic agent and metabolic syndrome modulator. Can theory translate into practice? The British Journal of Diabetes & Vascular Disease, July 1, 2005; 5(4): 209 - 216. [Abstract] [PDF]

				A. Kosaki, T. Hasegawa, T. Kimura, K. Iida, J. Hitomi, H. Matsubara, Y. Mori, M. Okigaki, N. Toyoda, H. Masaki, et al. Increased Plasma S100A12 (EN-RAGE) Levels in Patients with Type 2 Diabetes J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5423 - 5428. [Abstract] [Full Text] [PDF]

				V. R. Aroda and R. R. Henry Thiazolidinediones: Potential Link Between Insulin Resistance and Cardiovascular Disease Diabetes Spectr, April 1, 2003; 16(2): 120 - 125. [Abstract] [Full Text] [PDF]

				N. V. Chu, A. P. S. Kong, D. D. Kim, D. Armstrong, S. Baxi, R. Deutsch, M. Caulfield, S. R. Mudaliar, R. Reitz, R. R. Henry, et al. Differential Effects of Metformin and Troglitazone on Cardiovascular Risk Factors in Patients With Type 2 Diabetes Diabetes Care, March 1, 2002; 25(3): 542 - 549. [Abstract] [Full Text] [PDF]

				B. Gaster and I. B. Hirsch The Effects of Improved Glycemic Control on Complications in Type 2 Diabetes Arch Intern Med, January 26, 1998; 158(2): 134 - 140. [Abstract] [Full Text] [PDF]

				S. Lehto, T. Ronnemaa, K. Pyorala, and M. Laakso Predictors of Stroke in Middle-Aged Patients With Non–Insulin-Dependent Diabetes Stroke, January 1, 1996; 27(1): 63 - 68. [Abstract] [Full Text]